Stegmaier will also serve as Pediatric Oncology Chair at Dana-Farber
BOSTON, MA (Feb. 19, 2025) — Kimberly Stegmaier, MD, was named Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital and Chair of Pediatric Oncology at Dana-Farber Cancer Institute in an announcement made today. Her appointment is effective April 1, 2025.
A Dana-Farber, Boston Children’s Hospital, and Harvard Medical School faculty member since 2002 and Independent Investigator since 2006, Stegmaier is currently the Vice Chair for Pediatric Oncology Research at Dana-Farber, Co-Director of the Pediatric Hematologic Malignancy Program at Dana-Farber and Boston Children’s Hospital, Co-Leader for the Dana-Farber/Harvard Cancer Center Leukemia Program, and a Professor of Pediatrics at Harvard Medical School. She holds the Ted Williams Chair at Dana-Farber and is an Institute Member in the Cancer Program at the Broad Institute of Harvard & MIT.
“I have known and worked with Kim for many years and respect her as an outstanding physician-scientist. She has a passion for using basic discovery science to advance new treatments for pediatric cancer and a long-standing commitment to our patients, trainees and our program. I look for to working with her in the future,” said David A. Williams, MD, Chief of the Division of Hematology/Oncology at Boston Children’s Hospital; and Associate Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.
As Chair of Pediatric Oncology, Stegmaier will be responsible for the full scope of clinical, research, and educational activities of the department. She will work closely with David Williams, MD, Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, to lead the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
A highly skilled physician-scientist, Stegmaier is dedicated to the goal of precision pediatric oncology medicine, pioneering the development and application of innovative genomic approaches to identify new therapies for childhood cancer. She has focused her efforts on acute leukemias and pediatric solid tumors of childhood, particularly those driven by fusion oncoproteins. Her lab has discovered novel technologies, concepts, and targets with translational impact.
Stegmaier is a principal investigator and renowned scientist who has been recognized by a range of national and international organizations, including the National Cancer Institute, where she twice earned the NCI Outstanding Investigator Award, and the Society for Pediatric Research, where she received the E. Mead Johnson Award. A dedicated mentor, she was also the recipient of the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. Stegmaier is an elected member of the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI), as well as a Board Member of the American Association for Cancer Research (AACR).
She earned a BS from Duke University and an MD from Harvard Medical School, completed her residency at Boston Children’s, and a pediatric hematology-oncology fellowship at Dana-Farber/Boston Children’s.
###